EP3858859
AÐFERÐ VIÐ MEÐFERÐ Á KRABBAMEINI MEÐ ÓNÆMISEFTIRLITSHEMLI; MÓTEFNI SEM BINST PROGRAMMED DEATH-1 (PD-1) VIÐTAKA EÐA PROGRAMMED DEATH LIGAND 1 (PD-L1
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
14.7.2016EP published:
29.10.2025EP application number:
20214749.2
EP translation filed:
15.12.2025Grant published:
14.1.2026EPO information:
European Patent Register
Max expiry date:
13.7.2036Expiry date:
13.7.2026
Title in English:
METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)Language of the patent:
English
Timeline
Today
14.7.2016EP application
29.10.2025EP Publication
15.12.2025Translation submitted
14.1.2026Registration published
13.7.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
MANEKAS, DemetriosAddress:
Howell, New Jersey 07731, US
Name:
GROSSO, JosephAddress:
Princeton, New Jersey 08543, US
Name:
ANDERSON, JeffreyAddress:
Princeton, New Jersey 08543, US
Agent
Name:
Zacco Denmark A/SAddress:
Arne Jacobsens Allé 15, DK
Priority
Number:
201562192396 PDate:
14.7.2015Country:
US
Classification
Categories:
C07K 16/28, A61K 39/395, A61P 35/00, A61K 39/00, C12Q 1/6886, C12Q 1/70, G01N 33/574